Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases

Overall Portfolio Of 11 Products Includes Three From Two Unnamed Firms

 
• By Dean Rudge
  
Israel flag
Kamada’s typical focus is plasma-derived protein therapeutics • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products